

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

STA – Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company noted that socio-economic class, sex, age and race are risk factors for the development of heart failure. Socio-economic status also has an impact on access to secondary care in the UK, and subsequently access to heart failure treatments. Therefore, the company proposes a broad recommendation by NICE for empagliflozin (regardless of ejection fraction) that facilitates prescribing across primary and secondary care.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in the prevalence cannot be addressed in a technology appraisal.

The committee will consider whether its recommendations could have a detrimental impact on people protected by the equality legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope to highlight any potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during the scoping process

Approved by Associate Director (name): Ross Dent

Date: 06/07/2022